Right Ventricular Dysfunction in Patients Experiencing Cardiotoxicity during Breast Cancer Therapy
Table 5
Ventricular function parameters at the time of cardiotoxicity and at follow-up () in patients with and without left ventricular ejection fraction recovery to ≥55%.
(+) LV recovery
(−) LV recovery
Left ventricle
Baseline EF by MUGA (%)
62 ± 8
61 ± 4
Cardiotoxicity EF by MUGA (%)
49 ± 3
45 ± 3
Cardiotoxicity EF by ECHO (%)
49 ± 6
44 ± 6
Post-treatment EF by ECHO (%)
59 ± 2
48 ± 6
Cardiotoxicity GLS
−15.6 ± 2.8
−15.0 ± 1.9
Post-treatment GLS
−19.8 ± 2.3
−16.0 ± 1.8
Right ventricle
Baseline EF by MUGA (%)
48 ± 3
48 ± 4
Cardiotoxicity EF by MUGA (%)
41 ± 5
42 ± 4
Cardiotoxicity FAC by ECHO (%)
45 ± 3
42 ± 9
Post-treatment FAC by ECHO (%)
54 ± 4
43 ± 8
Cardiotoxicity RVFWLS
−25.3 ± 2.2
−24.8 ± 4.6
Post-treatment RVFWLS
−32.1 ± 5.3
−23.4 ± 3.8
Cardiotoxicity RVGLS
−21.1 ± 1.8
−20.2 ± 2.8
Post-treatment RVGLS
−24.6 ± 3.7
−22.1 ± 4.9
Abbreviations as per Table 2; recovery is defined as an LVEF ≥55% at last follow-up.
